CD274 and Patent ductus arteriosus: These observations, together with the recently initiated clinical trials involving CXCR4 antagonism with or without co-targeting of the PD-1:PD-L1 axis in PDA (NCT02179970; NCT02472977), attest to the clinical relevance of our findings.